

You are viewing an archived web page, collected at the request of [U.S Food and Drug Administration](#) using [Archive-It](#). This page was captured on 17:59:08 Jul 22, 2017, and is part of the [FDA.gov](#) collection. The information on this web page may be out of date. See [All versions](#) of this archived page. Found 0 archived media items out of 0 total on this page.

hide



[Home](#) [Drugs](#) [Drug Safety and Availability](#)

Drugs

Rhode Island: Attorney General Patrick C. Lynch



Department of Health and Human Services

Public Health Service
Food and Drug
Administration
Rockville MD 20857

January 28, 2005

Patrick C. Lynch
Attorney General of Rhode Island
150 South Main Street
Providence, Rhode Island 02903

Dear Mr. Lynch:

I write in response to the recently enacted law authorizing the Rhode Island Department of Health to license Canadian pharmacies to import prescription medications into the state of Rhode Island. It is my understanding that regulations will soon go into effect and the Rhode Island Board of Pharmacy may soon get applications from Canadian pharmacies for licenses.

FDA is very concerned about the safety risks associated with the importation of prescription drugs from foreign countries. In our experience, many drugs obtained from foreign sources that purport and appear to be the same as U.S. approved prescription drugs have been of unknown origin and quality. We cannot provide adequate assurance to the American public that the drug products delivered to consumers in the United States from foreign countries are the same products approved by FDA. For example, an American consumer recently ordered an FDA-approved anti-seizure medication called Neurontin from a website that purported to operate in Canada and to ship FDA-approved drugs from Canada into the United States. Nevertheless, the drug the consumer actually received had been manufactured in India, shipped from India, and was not approved by FDA for any use in the United States. In another instance, a website that purported to operate in Canada mailed insulin into the United States for use by an American with diabetes. Although the drug originally had been manufactured in the United States, it was shipped back into the country in a manner that did not satisfy the refrigeration storage conditions specified in FDA-approved labeling and, therefore, that could potentially compromise the safety and effectiveness of the insulin. Because the failure to refrigerate the product may not change its appearance, American consumers may have had no way of knowing if their insulin had been mishandled abroad.

These safety concerns are reflected in the import provisions of the Federal Food, Drug, and Cosmetic Act (FFDCA), which strictly limit the types of drugs that may be imported into the United States who may import them. Congress enacted these provisions to create a relatively "closed" drug distribution system, which helps ensure that the domestic drug supply is safe and effective. Accordingly, if an entity or person within the State of Rhode Island were to import prescription drugs into the State of Rhode Island from Canada, it would violate the FFDCA in virtually every instance. Furthermore, the drug importation scheme set forth by Congress preempts conflicting state or local legislation that would

legalize the importation of certain drugs from Canada in contravention of the FFDCA.

General Legal Framework

The starting point for our analysis is the legal framework applicable to imports of prescription drugs from Canada. ¹

First, virtually all drugs imported for personal use into the United States from Canada violate the FFDCA because they are unapproved (21 U.S.C. § 355), labeled incorrectly (21 U.S.C. §§ 352, 353), or dispensed without a valid prescription (21 U.S.C. § 353(b)(1)). Importing a drug into the United States that is unapproved and/or does not comply with the labeling requirements in the FFDCA is prohibited under 21 U.S.C. §§ 331(a), and/or (d).

FDA approvals are manufacturer-specific, product-specific, and include many requirements relating to the product, such as manufacturing location, formulation, source and specifications of active ingredients, processing methods, manufacturing controls, container/closure system, and appearance. 21 C.F.R. § 314.50. Generally, drugs sold outside of the United States are not manufactured by a firm that has FDA approval for that drug. Moreover, even if the manufacturer has FDA approval for a drug, the version produced for foreign markets usually does not meet all of the requirements of the United States approval, and thus is unapproved. 21 U.S.C. § 355. The version also may be misbranded because it may lack certain information that is required under 21 U.S.C. §§ 352 or 353(b)(2) but is not required in the foreign country, or it may be labeled in a language other than English (see 21 C.F.R. § 201.15(c)).

Second, with respect to "American goods returned," it is illegal for any person other than the original manufacturer of a drug to import into the United States a prescription drug that was originally manufactured in the United States and sent abroad (21 U.S.C. § 381(d)(1)). This is true even if the drug at issue were to comply in all other respects with the FFDCA. Importing a drug into the United States in violation of section 381(d)(1) is prohibited under 21 U.S.C. § 331(t).

Thus, to ensure compliance with the FFDCA, any state or private entity that intends to import prescription drugs into the United States must ensure, among other things, that it only imports FDA-approved drugs that comply with their FDA approvals in all respects, including manufacturing location, formulation, source and specifications of active ingredients, processing methods, manufacturing controls, container/closure system, and appearance. 21 C.F.R. § 314.50. The importer must also ensure that each drug meets all U.S. labeling requirements, and that such drugs are not imported in violation of the "American goods returned" provision in 21 U.S.C. § 381(d)(1).

Practically speaking, it is extremely unlikely that all of the applicable legal requirements will be met if Canadian pharmacies ship drugs into Rhode Island. Consequently, virtually every shipment would violate the FFDCA. Moreover, individuals or programs that cause illegal shipments also violate the FFDCA. 21 U.S.C. § 331 ("The following acts and the causing thereof are hereby prohibited...").

Potential Liability

There are many sources of civil and criminal liability for parties who violate the FFDCA. A court can enjoin violations of the FFDCA under 21 U.S.C. § 332. A person who violates the FFDCA can also be held criminally liable under 21 U.S.C. § 333. A violation of 21 U.S.C. §§ 331(a), (d), or (t) may be prosecuted as a strict liability misdemeanor offense. *See United States v. Dotterweich*, 320 U.S. 277, 284 (1943); 21 U.S.C. § 333(a)(1). Any such violation that is committed with intent to defraud or mislead or after a prior conviction for violating the FFDCA may be prosecuted as a felony under 21 U.S.C. § 333(a)(2). Separately, it is also a felony to knowingly import a drug in violation of the "American goods returned" provision of 21 U.S.C. § 381(d)(1). *See* 21 U.S.C. § 333(b)(1)(A). In addition, those who can be found civilly and criminally liable include all who *cause* a prohibited act under the FFDCA. 21 U.S.C. § 331 ("The following acts and the causing thereof are hereby prohibited")

To date, FDA has focused its enforcement resources on those who commercialize the practice of importing drugs into the United States from abroad. As a matter of enforcement discretion, FDA generally has not seized drugs from those who have taken buses across the border and then brought foreign drugs back into the United States for their own personal use. Instead, FDA has attempted to educate such citizens about the safety risks associated with consuming foreign drugs. Nevertheless, FDA retains the authority to bring an enforcement action in any case in which a provision of the FFDCA has been violated.

Federal Preemption

Federal preemption of state law is grounded in the Supremacy Clause of the United States Constitution. U.S. Const. art. VI, cl. 2. The Supremacy Clause states that: "This Constitution, and the Laws of the United States which shall be made in pursuance thereof . . . shall be the supreme Law of the Land; and the Judges in every State shall be bound thereby, any Thing in the Constitution or Laws of any State to the Contrary notwithstanding." U.S. Const. art. VI, cl. 2.

The Supreme Court has held that, under the Supremacy Clause, the enforcement of a state regulation may be pre-empted by federal law in several circumstances: first, when Congress, in enacting a federal statute, has expressed a clear intent to preempt state law; second, when it is clear, despite the absence of explicit preemptive language, that Congress has intended, by legislating comprehensively, to occupy an entire field of regulation and has thereby left no room for the States to supplement federal law; and finally, when compliance with both state and federal law is impossible, or when state law stands as an obstacle to the accomplishment and execution of the full purposes and objectives of Congress. *Capital Cities Cable, Inc. v. Crisp*, 467 US 691, 698-99 (1984) (quotation marks and citations omitted); see also *English v. General Electric Co.*, 496 US 72, 78-79 (1990); *Association of Int'l Auto Mfrs., Inc. v. Abrams*, 84 F.3d 602, 607 (2nd Cir. 1996).

Courts have thus held that federal law preempts state law when, *inter alia*, Congress has intended to occupy a field of regulation comprehensively (termed "field preemption") and when the federal law and the state law actually conflict (termed "implied conflict preemption"). See *English v. General Electric Co.*, 496 US at 78-79; *Choate v. Champion Home Builders Co.*, 222 F.3d 788, 792 (10th Cir. 2000).

Field Preemption

Congressional intent to occupy a field comprehensively can be shown any of three ways: 1) when, based on the pervasiveness of the federal regulation, it may be inferred that Congress "left no room for the States to supplement it"; 2) if the federal statute "touch[es] a field in which the federal interest is so dominant that the federal system will be assumed to preclude enforcement of state laws on the same subject"; or 3) when the state regulation "may produce a result inconsistent with the objective of the federal statute." *Rice v. Santa Fe Elevator Corp.*, 331 US 218, 230 (1947).

In the instant matter, Congress set forth a comprehensive importation scheme in the FFDCA that strictly limits the types of prescription drugs that are allowed to be introduced into domestic commerce. For example, the "American goods returned" provision (21 U.S.C. § 381(d)(1)) was enacted in 1988 as part of the federal Prescription Drug Marketing Act. PL. 100-293 (April 22, 1988). In enacting the law, Congress cited the explicit goal of limiting the flow of drugs into the United States from abroad. In section 2 of the bill, Congress found, "[l]arge amounts of drugs are being reimported into the United States as American goods returned. These imports are a health and safety risk to American consumers because they may have become subpotent or adulterated during foreign handling and shipping." *Id.* Clearly, Congress enacted section 381(d)(1) and the other import provisions in the FFDCA with the goal of controlling the types of drugs that could be legally imported into the United States. The federal scheme is comprehensive in that it promulgates national standards that are to be applied equally to all ports of entry, regardless of the states in which they are situated. By definition, the scheme cannot allow the individual states to enact laws that erode the federal standards; otherwise, importers could simply circumvent the federal law by routing all their unapproved drugs into the state (or states) that allowed such imports. Licensure of Canadian pharmacies by the state of Rhode Island would be inconsistent with the plain objectives of the FFDCA if such licensure authorized those Canadian pharmacies to ship into the United States drugs that violate the provisions of the FFDCA.

Implied Conflict Preemption

Implied conflict preemption can be shown in two ways: (1) where it is impossible to comply with both federal and state law; or (2) where the state law stands as an obstacle to the accomplishment and execution of the full purposes and objectives of Congress. See *English v. General Electric Co.*, 496 US at 79.

In the instant matter, if the state were to enact import legislation that contravened the provisions of the FFDCA, those importing the drugs would find it impossible to comply with both the state and the federal law. Indeed, the drugs imported pursuant to the state law would still be illegal under federal law (see 21 U.S.C. §§ 331, 352, 353, 355, and 381), and those importing the drugs would be subject to civil or criminal liability in the federal courts (21 U.S.C. §§ 331, 332, and 333).

In addition, a state law authorizing the importation of drugs would frustrate the Congressional objectives enshrined in the import provisions of the FDCA. As noted, Congress clarified the purpose behind 21 U.S.C. § 381(d)(1) when it passed the Prescription Drug Marketing Act. It concluded that American consumers are best protected by a "closed" drug system that strictly limits the types of products that may be imported into the United States. Any effort by the State of Rhode Island to allow imports that conflict with that scheme would stand as an obstacle to the accomplishment and execution of the full purposes and objectives of Congress as expressed in the FDCA.

Conclusion

I hope that the preceding discussion is helpful to you. The licensure of Canadian pharmacies by the State of Rhode Island will not only result in violations of federal law, it will put citizens at risk. In our experience, many drugs obtained from foreign sources that purport and appear to be the same as FDA-approved prescription drugs have been of unknown quality and origin. FDA approves a drug based on scientific data submitted by the drug sponsor to demonstrate that the drug is safe and effective. We cannot provide adequate assurance to the American public that the drug products delivered to consumers in the United States from foreign countries are the same products approved by FDA. Accordingly, the FDCA strictly limits the types of prescription drugs that may be imported into the United States. Any state law that legalizes imports in contravention of the FDCA would be preempted by federal law. Moreover, those importing drugs in violation of the FDCA would be subject to liability under that statute, regardless of whether the importation was otherwise sanctioned by the state.

We are aware that the high cost of some prescription drugs is a serious public health issue, and we have taken several steps in recent months to help reduce the cost of drugs in the United States without opening our borders to the potential dangers of foreign unapproved pharmaceuticals. These steps include new initiatives to accelerate approval of innovative medical procedures and drug therapies, changes to our regulations to reduce litigation that has been shown to delay unnecessarily access to more affordable generic drugs, and proposals to increase agency resources for the review and approval of generic drugs – products that are often far less expensive than brand name products in the U.S., and generally less expensive than the generic drugs sold elsewhere in the industrialized world. Also, the Medicare prescription drug discount card provides millions of America's seniors with discounts and coverage for their prescription medicines.

If you need additional information, please feel free to contact me.

Sincerely,

William K. Hubbard
Associate Commissioner for Policy
and Planning

Footnote

1 We will limit our discussion to drugs imported from Canada because the Rhode Island law is so limited. The legal analysis is the same for drugs imported from any foreign country.

Page Last Updated: 09/10/2009

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

Language Assistance Available: [Español](#) | [繁體中文](#) | [Tiếng Việt](#) | [한국어](#) | [Tagalog](#) | [Русский](#) | [العربية](#) | [Kreyòl Ayisyen](#) | [Français](#) | [Polski](#) | [Português](#) | [Italiano](#) | [Deutsch](#) | [日本語](#) | [فارسی](#) | [English](#)

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA](#) [No FEAR Act](#) [Site Map](#) [Nondiscrimination Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)